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adults. Over three-fourths of older adults with depression use antidepressants for
annual expenditure of nearly $10 billion, mostly for SNRIs and SSRIs.
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OBJECTIVES: Polypharmacy has now become a norm instead of an exception in the
treatment of pediatric bipolar disorder (PBD). The objective of the study was to
identify the most commonly used psychotropic combinations in PBD patients and
to evaluate the se ’ adherence patterns of the combination regimens. METHODS:
2003-2007 Medicaid Analytic eXtract (MAX) data files from 4 US states were used.
Children and adolescents (6-18 years)were identified if theywere newly discharged
fromahospitalwith bipolar disorder as their primary diagnosis. Polypharmacywas
operationally defined as at least 14 days overlap between the episodes of 2 psycho-
tropic drugs. These patients were followed for a year since their hospital discharge
to observe the adherence patterns. Adherence for combination regimenswasmea-
sured usingmedication possession ratio (MPR), calculated for each individual drug
separately and compared with the adherence when the drug was used alone. Mul-
tivariate logistic regression analysis was performed to examine the factors associ-
ated with treatment adherence. RESULTS: Of the 7337 PBD patients identified,
about 70% (n5142) received combination treatments, and 62% (n4540) received
combinations of an atypical antipsychotic plus a mood stabilizer. Overall MPRs for
monotherapy and polypharmacy users were 0.69(0.26) and 0.74(.024), respec-
tively. Multivariate analysis revealed that the combination users had higher MPRs
as compared to the correspondentmonotherapy users.When compared to atypical
antipsychotic monotherapy users, combination users who initiated with an atyp-
ical monotherapy (OR1.3;CI1.12-1.5), atypical plus mood stabilizer(OR1.27;
CI1.1-1.47) and two atypicals (OR2.45;CI1.26-4.74) were all associatedwith bet-
ter compliance. Other factors associated with higher MPRs were being white
(O.R1.71;C.I.1.48-1.98) and foster care (O.R.2.19;C.I.1.91-2.51). Older age group
(13-18 years) (O.R0.81;C.I.0.71-0.92), however, was associated with having lower
MPRs. CONCLUSIONS: Psychotropic polypharmacy is common among children and
adolescents with bipolar disorder. Addition of another psychotropic medication to
monotherapy regimen often leads to improvement in medication adherence.
PMH73
ESTIMATING OFF-LABEL USE OF PRESCRIPTION DRUGS: THE CASE OF
GABAPENTIN
Khan N1, Kaestner R2, Walton S2, Yarnoff B2
1Oxford Outcomes Ltd., Morristown, NJ, USA, 2University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: Studies have indicated that approximately 80 to 95 percent of gaba-
pentin use is off-label. However, evidence in support of these off label uses is
limited. There is an increasing body of research on the efficacy of gabapentin for
treating pain and mental conditions, but much of this work (especially that for
mental conditions) is preliminary and suggestive at best. The objective of this study
is to examine, using a nationally representative sample, the efficacy of gabapentin
in treating the wide range of off-label conditions for which there is little or no
evidence and the few conditions for which there is already some evidence.
METHODS: The study uses the 1997-2007 Medical Expenditure Panel Data set. Us-
ers of gabapentin were identified and the top 20 ICD9 Codes, by age group, associ-
ated with prescriptions for gabapentin were used to select control subjects. Sub-
samples associated with pain, neurologic conditions, mental health, and other
off-label conditions were created. Ordinary least squares and propensity score
matching following the regression method attributed to Hirano and Imbens were
used to examine the association of gabapentin and self-reported health (physical
and mental health) with controls for lagged health, age, gender, race, income,
education, insurance, and co-morbidities. RESULTS: Use of gabapentin was nega-
tively associated with reporting of good physical or mental health in almost all
cases. The coefficients in the propensity score controlled models tended to be
smaller but still suggested a significant relationship between gabapentin use and a
5-10% lower probability of reporting good physical or mental health.
CONCLUSIONS: There was little evidence that the use of gabapentin is associated
with better self-reported physical or mental health and lower medical spending.
There is a strong case for improved efforts to promote evidence based use of med-
ications as there is a potential for significant expenditures with little or no impact
on health.
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OBJECTIVES: Antidepressant prescribing have changed globally over the last few
years, with conventional drugs like tricyclics and MAO inhibitors being gradually
replaced by selective serotonin reuptake inhibitors (SSRIS) and novel antidepres-
sants. The prescribing of antidepressants varies by country, and the type of anti-
depressant chosen is influenced by both physician and patients. The aim of this
study was to assess prescribing and usage pattern of antidepressant medications
and cost of them.METHODS: A retrospective cross-sectional study was carried out
on insurance prescriptions during 3 years from2007 to 2009. All insurance prescrip-
tions were collected using especial software called Rx Analyst during the study
period in the National Committee of Rational Drug Use, and then reviewed for
prescriptions included at least one dosage form of antidepressants. Data related to
dispensing of antidepressants were obtained from the official databank of national
regulatory authority. Drugs were classified according to the Anatomic Therapeutic
Chemical (ATC-1999 edition) System. RESULTS: A total of more than 224 million
prescriptions were reviewed. The number of antidepressants that prescribed were
134 million (4.18%), 155 million (4.34%) and 173 million (4.17%) in 2007, 2008, and
2009, respectively. Meanwhile, the number which dispensed from wholesaler to
retail pharmacies in that period was 945 million (3.23%), 960 million (3.33%), and 1
billion (3.35%) in 2007, 2008, and 2009, respectively. Themost frequently prescribed
substances were nortriptylline, fluoxetine, and citalopram, which accounted for
67% of all prescriptions. The total price of antidepressant prescribed during study
period was 15264270 US$ and total sale was 111442111 US$ obtained from national
sale data. CONCLUSIONS: There is a remarkable variation in antidepressants pre-
scribing and dispensing that might be related to self-medication of these com-
pounds. A multi interventional policy including educational, regulatory, manage-
rial, and financial strategies for professions andpublic should be planed to promote
rational use of antidepressant medications.
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Sedative hypnotic drugs are widely used to treat sleep disorders, but it is unclear
how their utilization varies by drug and patient diagnosis. OBJECTIVES: TO DE-
SCRIBE UTILIZATION PATTERNS FOR VARIOUS SEDATIVE HYPNOTIC DRUGS IN
PATIENTS WITH AND WITHOUT A CLAIM FOR INSOMNIA. METHODS: This study
was a cohort analysis of sedative hypnotic utilization in the US-based Marketscan
commercial health care claims database for 2008-2010. Patients included those
with and without an ICD-9 code for insomnia who were treated with sedative
hypnotics including zolpidem, zaleplon, eszopiclone, and selected benzodiaz-
epines (alprazolam, lorazepam, and diazepam). Outcomes includedmean andme-
dian number of prescriptions filled, duration between refills, and switching pat-
terns over 1 year of follow-up. RESULTS: A substantial proportion of sedative
hypnotic use (55-92%, depending on the drug) is in patients without an insomnia
diagnosis. Themeannumber of prescriptionswas consistently higher in thosewith
than without an insomnia diagnosis. In zolpidem, those with an insomnia diagno-
sis received amean of 4.8 (95% CI 4.76-4.81) prescriptionswithin a year, while those
without an insomnia claim received 2.8 (95%CI 2.82-2.84). Similarly, the duration of
time between refills was lower for those with than without an insomnia claim; for
zolpidem, themean number of days between refills was 63.3 and 83.6, respectively.
The duration between prescriptions also varied by drug, with zolpidem and eszo-
piclone having a shorter mean number of days between refills than zaleplon or the
benzodiazepines (75, 65, 84 or 90, respectively). More patients with than without
insomnia claims (26.7% vs. 9.4%) switched from one sedative hypnotic drug to
another. CONCLUSIONS:Drug utilization in users of sedative hypnotics varies sub-
stantially by diagnosis and drug. Those with claims for insomnia receive drug for
longer periods of time, and with less time between refills than those without doc-
umented insomnia diagnoses.
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OBJECTIVES: In April 2005, the Food and Drug Administration (FDA) issued a black
box warning (BBW) regarding the risks of using atypical antipsychotics (AAPs) for
behavioral disorders in elderly patientswith dementia. The objective of the present
studywas to investigate the impact of the BBWon the utilization of AAPs in elderly
non-institutionalized dementia population.METHODS:Medical Expenditure Panel
Surveys, from year 2004 through 2007, were used in the study. Utilization rates of
AAPs pre-warning (2004-2005) and post-warning (2006-2007) weremeasures of pri-
mary interest in both overall and Medicare samples. Chi-square tests and multi-
variate logistic regression analyses were performed to examine pre-post differ-
ences in utilization rates (defined as elderly patients taking at least onemedication
associated with dementia) and gain insights into patterns of AAP use with respect
to demographic, insurance and other factors. RESULTS: AAP use declined in the
post-warning period for the main sample (X2 0.81, p0.3668) as well as Medicare
sample (X2 2.72, p0.0992). However the decline was not statistically significant.
Additionally, bivariate analyses of the main sample showed significantly higher
proportion of patients receiving AAPs in the post-warning period for individuals
with prescription drug coverage (x2 21.63, p 0.0001). In contrast, a similar anal-
ysis for the Medicare sample revealed significantly higher proportion of patients
receiving AAPs in the post-warning period for people with no Medicare drug cov-
erage (x2 20.83, p 0.0001). Further, logistic regression analyses showed no sig-
nificant decline in the use of AAPs in the post-warning period for the main sample
(Odds Ratio, OR  0.831, CI  0.366 – 1.885) as well as the Medicare sample (OR
0.798, CI 0.364 – 1.753). CONCLUSIONS: The regulatory warnings and labeling
changes regarding off-label use of AAPs in dementia treatment seem to havemade
little impact on the actual use in non-institutionalized populations.
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